Artemis Investment Management LLP decreased its holdings in Zoetis Inc (NYSE:ZTS) by 39.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 495,978 shares of the company’s stock after selling 321,814 shares during the quarter. Artemis Investment Management LLP’s holdings in Zoetis were worth $65,598,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Corbenic Partners LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $31,000. Johanson Financial Advisors Inc. acquired a new stake in shares of Zoetis during the 4th quarter worth $623,000. Appleton Partners Inc. MA increased its holdings in shares of Zoetis by 6.4% during the 4th quarter. Appleton Partners Inc. MA now owns 92,261 shares of the company’s stock worth $12,211,000 after buying an additional 5,527 shares during the last quarter. Central Bank & Trust Co. raised its position in shares of Zoetis by 6.6% in the 4th quarter. Central Bank & Trust Co. now owns 7,863 shares of the company’s stock worth $1,041,000 after buying an additional 485 shares during the period. Finally, DNB Asset Management AS raised its position in shares of Zoetis by 2.7% in the 4th quarter. DNB Asset Management AS now owns 156,516 shares of the company’s stock worth $20,715,000 after buying an additional 4,062 shares during the period. Institutional investors own 89.96% of the company’s stock.

NYSE:ZTS traded up $0.60 during mid-day trading on Tuesday, hitting $137.11. The company had a trading volume of 56,362 shares, compared to its average volume of 1,576,549. The business has a fifty day simple moving average of $128.14 and a 200-day simple moving average of $123.19. The company has a current ratio of 4.39, a quick ratio of 3.02 and a debt-to-equity ratio of 2.47. Zoetis Inc has a 1 year low of $82.26 and a 1 year high of $136.75. The firm has a market capitalization of $64.57 billion, a price-to-earnings ratio of 43.82, a PEG ratio of 2.94 and a beta of 0.81.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same quarter in the prior year, the business earned $0.83 earnings per share. The company’s revenue was up 7.0% compared to the same quarter last year. As a group, research analysts anticipate that Zoetis Inc will post 3.6 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Friday, January 17th will be issued a dividend of $0.20 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Thursday, January 16th. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.

A number of equities research analysts have issued reports on ZTS shares. Morgan Stanley boosted their price target on Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a research report on Monday, September 30th. ValuEngine downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America reaffirmed a “hold” rating and issued a $125.00 price objective on shares of Zoetis in a research note on Thursday, December 5th. Credit Suisse Group set a $138.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Friday, October 11th. Finally, Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $142.00 target price for the company in a report on Thursday, December 26th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Zoetis presently has an average rating of “Buy” and a consensus price target of $127.47.

In related news, EVP Kristin C. Peck sold 11,500 shares of Zoetis stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $117.16, for a total transaction of $1,347,340.00. Following the sale, the executive vice president now owns 44,877 shares of the company’s stock, valued at approximately $5,257,789.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction on Monday, December 16th. The stock was sold at an average price of $124.93, for a total transaction of $764,946.39. Following the sale, the executive vice president now directly owns 34,027 shares in the company, valued at approximately $4,250,993.11. The disclosure for this sale can be found here. Insiders have sold a total of 123,917 shares of company stock worth $14,797,192 over the last three months. 0.29% of the stock is currently owned by corporate insiders.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: Bid-Ask Spread

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.